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Are we facing an opioid crisis in Europe? 
Over the past 15 years, an increasing use of opioids 
has been reported in the USA and Canada, coinciding 
with an increase in opioid addiction, opioid-related 
morbidity, and opioid-related mortality. Indeed, in the 
USA approximately 130 patients die from an overdose 
of prescription opioids each day.1 The opioid epidemic 
has been well documented in the USA and Canada, but 
fewer data are available for Europe.2 
In The Lancet Public Health, Kalkman and colleagues3 
report important results from a retrospective, multi-
source database study investigating opioid use as well 
as proxies for opioid misuse in the Netherlands between 
2008 and 2017. The authors show that, over this 10-year 
period, the overall number of opioid prescriptions 
nearly doubled, mainly because of an increase in oxy-
codone users from 574 to approximately 2500 per 
100 000 inhabitants. Misuse of prescription opioids 
also grew. The authors report increases in the number 
of hospital admissions related to prescription opioid 
intoxication, in the proportion of patients receiving 
addiction care for prescription opioid use disorder, and 
in prescription opioid-related mortality over the study 
period. In this same period  the number of patients 
receiving addiction care for heroin use disorder and 
substitution therapy decreased whereas the mortality 
rate and hospitalisation for heroin and substitution 
therapy remained stable. Nevertheless, opioid misuse 
in the Netherlands is still substantially lower than in 
the USA and Canada. Data from the 2018 report by the 
International Narcotics Control Board show that the 
USA is the number one consumer of narcotic drugs, 
with 40 240 defined daily dosages of opioids per million 
inhabitants per day. In second place is Germany with 
28 862 defined daily dosages per 1 million inhabitants, 
followed by Canada with 26 029. The Netherlands is 
in ninth place, with 16 114 defined daily dosages per 
1 million inhabitants. Although the USA is the number 
one consumer, a 13% decrease in consumption was 
observed compared with the previous report from 
2014–16, whereas an 8% increase was observed for the 
Netherlands. This suggests that preventive measures 
taken in the USA such as physician awareness and new 
policies for opioid prescribing are starting to pay off.4,5
In the Netherlands, 83 individuals died because of 
prescription opioid overdose in 2017, with an incidence 
of 0·5 deaths per 100 000 inhabitants. In the USA, opioid-
related mortality is ten times higher, with 5·2 deaths per 
100 000 inhabitants in 2016.6 This lower mortality in the 
Netherlands might be related to differences in health-
care access, better patient monitoring, and avoidance of 
chronic opioid use, which is a known risk factor of misuse 
and overdose.4 Although Kalkman and colleagues3 could 
not investigate the duration of opioid use, a recent 
paper7 on extramural opioid use in the Netherlands 
reported that most opioids (79%) were prescribed for 
short durations (<4 months). Thus, although the use 
of opioids (in particular oxycodone) is on the rise in the 
Netherlands, epidemic proportions have not yet been 
reached. 
The opioid epidemic in the USA has been attributed 
to multiple factors, including the publication of influen-
tial reports stating that opioids were safe, aggressive 
marketing, existence of so-called pill mills (pharmacies 
or clinics that inappropriately dispense opioids), and new 
attitudes towards pain manage ment.2,8 This situation is 
different from the Netherlands, where public marketing 
by pharmaceutical companies is not allowed and pill 
mills do not exist. Instead, the increase in opioid use 
has been related to easy access to opioid drugs (through 
GPs and specialists, and for legiti m ate medical needs), 
aversion to non-steroidal anti-inflammatory drugs, 
and more attention to pain therapy. Indeed, opioids are 
no longer only used to treat cancer pain, but also for 
the symptomatic relief of non-cancer related chronic 
pain. Moreover, patients are being discharged sooner 
after surgery for health economic purposes, so acute 
pain relief has become more import ant. Adequate pain 
relief is one of the quality indicators used by the Dutch 
government to benchmark hospitals.9
A limitation of the study by Kalkman and colleagues3 
is that the authors were not able to investigate risk 
factors for opioid misuse, as information on patient 
sex, age, and mental health status, type of prescriber, 
and indication of use was not available. Additionally, 
codeine was excluded from all analyses because it 
is not exclusively prescribed for pain relief, and the 
paracetamol-codeine combination tablet is no longer 
reimbursed in the Netherlands since 2013. 
Safe and appropriate use of opiates is crucial, and the 
findings presented by Kalkman and colleagues3 are a call 
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for action. In the Netherlands more than 80% of opioids 
are prescribed by general practitioners, so the primary 
care standard on chronic pain was recently updated 
to highlight the importance of an interdisciplinary 
approach to pain management and of restricting the 
indication of opioids. Other key topics for research are 
non-addictive painkillers stronger than paracetamol 
or NSAIDS, and evidence-based methods to effectively 
treat opioid addiction in those who misuse these drugs. 
Finally, the public perception of pain treatment should 
be addressed—discussing the pros and cons, informing 
patients, and agreeing on realistic goals might prevent 
addiction.
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